Loading…
Loading…
EQUITY / NYSE · XASE
China Pharma Holdings, Inc.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.665 USD · 1.8377%
Observed: Oct 6, 2026, 3:24 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/05/2026 · 0.653 USD · Volume 118,444
63 actual observations · Latest bar: 2026-10-05 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Revenue | 948,340 USD | 1,025,767 USD | -7.55% |
| Operating profit | -1,431,845 USD | -652,120 USD | — |
| Net income | -1,458,123 USD | -528,367 USD | — |
| Cash and cash equivalents | 304,874 USD | — | — |
| Total liabilities | 8,528,623 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 304,874 USD | — | — | 345,112 USD | 345,112 USD | 267,625 USD | — | — |
| Gross profitIncome statement | 83,566 USD | 369,053 USD | — | — | -131,950 USD | -59,654 USD | -282,725 USD | -87,010 USD |
| Net incomeIncome statement | -1,458,123 USD | -2,601,271 USD | -1,143,148 USD | — | -3,187,556 USD | -651,482 USD | -1,965,421 USD | -528,367 USD |
| Operating profitIncome statement | -1,431,845 USD | -2,549,109 USD | — | — | -3,239,078 USD | -628,145 USD | -2,038,883 USD | -652,120 USD |
| RevenueIncome statement | 948,340 USD | 1,931,876 USD | — | — | 4,144,268 USD | 756,217 USD | 2,918,271 USD | 1,025,767 USD |
| Total assetsBalance sheet | 44,709,903 USD | — | — | 30,999,464 USD | 30,999,464 USD | 15,804,793 USD | — | — |
| Total equityBalance sheet | 36,181,280 USD | — | 37,024,190 USD | 22,739,752 USD | 22,739,752 USD | 8,313,997 USD | — | 6,461,744 USD |
| Total liabilitiesBalance sheet | 8,528,623 USD | — | — | 8,259,712 USD | 8,259,712 USD | 7,490,796 USD | — | — |
| Financing cash flowCash flow statement | — | 40,793 USD | — | — | -294,027 USD | — | -221,435 USD | — |
| Operating cash flowCash flow statement | — | -88,120 USD | — | — | 148,261 USD | — | -3,729 USD | — |
| Capital expendituresCash flow statement | — | — | — | — | 59,324 USD | — | 58,870 USD | — |
| Investing cash flowCash flow statement | — | — | — | — | -137,251 USD | — | -131,484 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 04/01/2026 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.